Biologics

Johnson & Johnson has partnered with the U.S. administration to lower drug prices and expand its domestic footprint. This agreement will provide millions of Americans with access to discounted pharmaceuticals and exempt these medicines from U.S. tariffs. The company is reinforcing its $55 billion U.S. investment, with plans for two new advanced manufacturing facilities for cell therapies and biologics, creating thousands of jobs and demonstrating a commitment to U.S.-based production and innovation.

WuXi Biologics secured three awards at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025, including “CDMO of the Year – Asia Pacific.” The awards recognize WuXi Biologics’ excellence in biomanufacturing, R&D, technological innovations, and partnerships. The company’s integrated platform streamlines biologics development, achieving a 6-month DNA-to-IND timeline for monoclonal antibodies. With a 100% PLI success rate and multiple regulatory inspections, WuXi Biologics offers end-to-end solutions to over 1000 clients globally. CEO Dr. Chris Chen attributes the success to the company’s commitment to quality and innovation.

Evotec SE has entered a non-binding agreement with Sandoz AG for the potential sale of its Just – Evotec Biolog